“We cut banking to underweight (earlier overweight) by removing IndusInd Bank and cutting State Bank of India (SBI). We also remove Kajaria Ceramics. We increase weight in IT (evenly between Infosys, HCL Technologies and TCS) and make it overweight. The other defensive weight addition is consumer staples to Neutral (big underweight earlier) with Hindustan Unilever (HU) being made neutral and the addition of Marico and Colgate,” wrote Mahesh Nandurkar, managing director at Jefferies in a recent co-authored note with Abhinav Sinha.
At the bourses, sectoral indexes of the classic defensives plays - fast moving consumer goods (FMCG), pharma and information technology (IT) have done well in the last one month compared to nearly 2 per cent fall in the Nifty50.
The Nifty IT index has been among the key gainers, up 5.2 per cent since then. Nifty FMCG and Nifty Pharma indices, too, have surged around 4 per cent and 3 per cent respectively during this period, ACE Equity data show. On the other hand, investors have dumped cyclical plays, such as banks and real estate with both the respective indices on the NSE slipping 7 per cent to 9 per cent during this period.
Vaibhav Sanghavi, co-chief executive officer, Avendus Capital Public Markets
Alternate Strategies, too, believes that markets
are likely to prefer defensive stocks
in the near-term amid rising Covid cases. Over the medium-to-long term, however, the money may shift back to cyclicals as vaccination and economic recovery gathers pace, he says.
“The first half of the March 2020 quarter results season is IT heavy. The consensus expectation is that the companies will report good numbers and stable guidance. This, along with the Covid-related developments will keep IT, FMCG and pharma stocks in focus. On its part, the Reserve Bank of India (RBI) is trying to keep interest rates and the yield curve in check as the economy recovers,” Sanghavi said.
Besides Covid-19 cases, pace and efficacy of vaccination markets
will keep a tab on corporate results and the guidance given by companies, bond yields, policy measures of global central banks and oil prices.
“Expeditious containment of Covid cases and accelerated pace of vaccination will provide comfort for FY22 economic growth recovery. Secondly, the expectations for FY22 earnings are running high at over 30 per cent growth in Nifty fiscal 2021-22 (FY22) EPS. Given the rich valuations, any misses on FY22 earnings delivery may act as a dampener,” said Gautam Duggad, head of institutional research at Motilal Oswal Securities.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.